Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
2.630
+0.010 (0.38%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.

Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers.

The company is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd.
Alpha Tau Medical logo
Country Israel
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 125
CEO Uzi Sofer

Contact Details

Address:
Kiryat HaMada St. 5
Jerusalem, 9777605
Israel
Phone 972 3 577 4115
Website alphatau.com

Stock Details

Ticker Symbol DRTS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001871321
CUSIP Number M0740A108
ISIN Number IL0011839383
SIC Code 3841

Key Executives

Name Position
Uzi Sofer Chief Executive Officer and Chairman
Raphi Levy Chief Financial Officer
Amnon Gat Chief Operations Officer
Ronen Segal Chief Technology Officer
Dr. Robert B. Den M.D. Chief Medical Officer and Member of Scientific Advisory Board
Prof. Yona Keisari Chief Scientific Officer and Member of Scientific Advisory board
Rebecca Becker Vice President of legal
Peter M. Melnyk Chief Commercial Officer
Prof. Itzhak Kelson Chief Physics Officer and Member of Scientific Advisory Board
Yael Zeiger Corporate Controller

Latest SEC Filings

Date Type Title
Apr 2, 2025 6-K Report of foreign issuer
Mar 12, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 12, 2025 6-K Report of foreign issuer
Mar 12, 2025 20-F Annual and transition report of foreign private issuers
Feb 27, 2025 6-K Report of foreign issuer
Feb 24, 2025 6-K Report of foreign issuer
Feb 3, 2025 6-K Report of foreign issuer
Jan 27, 2025 6-K Report of foreign issuer
Dec 18, 2024 6-K Report of foreign issuer
Dec 17, 2024 6-K Report of foreign issuer